Sanofi Wins U.S. FDA Approval for Multiple Sclerosis Pill

Sanofi (SAN)won U.S. backing to sell the multiple sclerosis pill Aubagio, enabling the drugmaker to enter a $12 billion industry, even as analysts said the medicine may be overshadowed by more effective products.

The Food and Drug Administrationapproved the once-a-day medicine for relapsing forms of the debilitating disease, the agency said yesterday in a statement. The treatment, also known by the scientific name of teriflunomide, is for patients in the initial phases of the disease, Paris-based Sanofi said.

Read the full story:

Source: Bloomberg